Whole Body Positron Emission Tomography/Computed Tomography (PET/CT) in the Evaluation of Ophthalmic Tumors

Abstract

The clinical value of whole body positron emission tomography/computed tomography (PET/CT) as an imaging tool in diagnosis of ophthalmic tumors was investigated. The retrospective observational case series were performed on the patients with suspected ophthalmic tumors who underwent whole body PET/CT. The golden standard of diagnosis was the final pathological diagnosis or the results of long-term follow-up for patients without surgery/biopsy. PET/CT findings were compared with the golden standard. The sensitivity, specificity, accuracy and positive likelihood ratio of PET/CT in the detection of ophthalmic tumors were calculated. The clinical application of PET/CT in different types of ophthalmic tumors was evaluated. The results showed that 30 patients (18 males and 12 females) with a mean age of 43.0 years (range 4–63 years) were collected. The mean sizes of orbital tumors and intraocular tumors were 26.8 mm×17.8 mm and 11.2 mm×6.1 mm, respectively. The overall sensitivity, specificity, accuracy and positive likelihood ratio of whole body PET/CT in ophthalmic tumors were 76.5%, 71.4%, 75.0% and 2.67, and were 62.5%, 100% and 70.0% in intraocular tumors, and those were 100%, 60.0% and 84.6% in orbital tumors, respectively. PET/CT findings were applied to help make appropriate treatment options in 27 out of 30 patients (90.0%), and 12 (40.0%) patients changed the treatment strategy. False negative results in 4 cases and false positive results in 2 cases were observed in this series. It was suggested that PET/CT was an effective imaging modality in detecting, diagnosing and developing therapeutic schedule for patients with ophthalmic tumors. It was more sensitive and accurate for detecting orbital tumors than for detecting intraocular tumors.

Keywords

positron emission tomography/computed tomography / ophthalmic tumor / orbital tumor / ocular tumor

References

[1] EndoK, OriuchiN, HiguchiT, et al.. PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol, 2006, 11(4): 286-296

[2] PoeppelTD, KrauseBJ, HeusnerTA, et al.. PET/ CT for the staging and follow-up of patients with malignancies. Eur J Radiol, 2009, 70(3): 382-392

[3] SachelarieI, KerrK, GhesaniM, et al.. Integrated PET-CT: evidence-based review of oncology indications. Oncology (Williston Park), 2005, 19(4): 481-490

[4] RoeRH, FingerPT, KurliM, et al.. Whole-body positron emission tomography/computed tomography imaging and staging of orbital lymphoma. Ophthalmology, 2006, 113(10): 1854-1858

[5] FingerPT, ChinKJ. [(18)F]Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) physiologic imaging of choroidal melanoma: before and after ophthalmic plaque radiation therapy. Int J Radiat Oncol Biol Phys, 2011, 79(1): 137-142

[6] FingerPT, KurliM, ReddyS, et al.. Whole body PET/ CT for initial staging of choroidal melanoma. Br J Ophthalmol, 2005, 89(10): 1270-1274

[7] RadhakrishnanV, KumarR, MalhotraA, et al.. Role of PET/CT in staging and evaluation of treatment response after 3 cycles of chemotherapy in locally advanced retinoblastoma: a prospective study. J Nucl Med, 2012, 53(2): 191-198

[8] MatsuoT, OginoY, IchimuraK, et al.. Clinicopathological correlation for the role of fluorodeoxyglucose positron emission tomography computed tomography in detection of choroidal malignant melanoma. Int J Clin Oncol, 2014, 19(2): 230-239

[9] ReddyS, KurliM, TenaLB, et al.. PET/CT imaging: detection of choroidal melanoma. Br J Ophthalmol, 2005, 89(10): 1265-1269

[10] FaiaLJ, PulidoJS, DonaldsonMJ, et al.. The relationship between combined positron emission tomography/computed tomography and clinical and light microscopic findings in choroidal melanoma. Retina, 2008, 28(5): 763-769

[11] PapastefanouVP, IslamS, SzyszkoT, et al.. Metabolic activity of primary uveal melanoma on PET/CT scan and its relationship with monosomy 3 and other prognostic factors. Br J Ophthalmol, 2014, 98(12): 1659-1665

[12] FingerPT, ChinK, IacobCE. 18-Fluorine-labelled 2-deoxy-2-fluoro-D-glucose positron emission tomography/computed tomography standardised uptake values: a non-invasive biomarker for the risk of metastasis from choroidal melanoma. Br J Ophthalmol, 2006, 90(10): 1263-1266

[13] CalcagniML, MattoliMV, BlasiMA, et al.. A prospective analysis of (1)(8)F-FDG PET/CT in patients with uveal melanoma: comparison between metabolic rate of glucose (MRglu) and standardized uptake value (SUV) and correlations with histopathological features. Eur J Nucl Med Mol Imaging, 2013, 40(11): 1682-1691

[14] McCannelTA, ReddyS, BurgessBL, et al.. Association of positive dual-modality positron emission tomography/computed tomography imaging of primary choroidal melanoma with chromosome 3 loss and tumor size. Retina, 2010, 30(1): 146-151

[15] PatelP, FingerPT. Whole-body 18F FDG positron emission tomography/computed tomography evaluation of patients with uveal metastasis. Am J Ophthalmol, 2012, 153(4): 661-668

[16] GuptaS, BhattVR, VarmaS. Unilateral orbital pain and eyelid swelling in a 46-year-old woman: orbital metastasis of occult invasive lobular carcinoma of breast masquerading orbital pseudotumour. BMJ Case Rep, 20112011

[17] KubotaR, YamadaS, KubotaK, et al.. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med, 1992, 33(11): 1972-1980

[18] KimKS. Primary nasopharyngeal tuberculosis mimicking carcinoma: a potentially false-positive PET/CT finding. Clin Nucl Med, 2010, 35(5): 346-348